Sdalmo (amlodipine) – New drug approval
July 24, 2025 - The FDA approved Brillian’s Sdalmo (amlodipine), which may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension, to lower blood pressure in adults and pediatric patients 6 years of age and older and for coronary artery disease (CAD) in adults (chronic stable angina, vasospastic angina [Prinzmetal's or variant angina], and angiographically documented CAD in patients without heart failure or an ejection fraction < 40%).